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Class III medical devices, which are high-risk devices such as pacemakers 
and cardiovascular stents, must demonstrate evidence of safety and effectiveness 
in clinical trials prior to approval by the Food and Drug Administration 
(FDA).1 In these clinical trials, patients are often, but not always, randomized 
into study conditions: a treatment group that receives the medical device, and a 
control group that does not. Randomization controls for extraneous differences 
between patients, and investigators can then determine how likely it is that the 
differences between the treatment and control group are related to chance.2 
While randomization is one element of a high-quality clinical trial, the oth-
er two components—blinding and placebo-control condition—are generally 
absent because of the nature of the intervention studied. That is, it may be diffi-
cult, impracticable, or possibly unethical to design a clinical trial in which both 
the subject and the investigator are blinded as to who has received the medical 
device, and in which a sham device is used as a control for the placebo effect, 
the presence and power of which have been well documented in behavioral sci-
ence and medical research.3 
Given the absence of blinding and placebo-controls, bias of an unknown 
size is present in studies of Class III devices. This is because investigators and 
patients may unintentionally change their behavior in response to knowledge 
about who is in the treatment and control conditions, which can affect study 
 * Yale Law School, J.D. expected 2016; University of Arizona, Ph.D. in Sociology 
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 1. 21 C.F.R. § 860.7(c) (2012).  
 2. Peter Armitage, The Role of Randomization in Clinical Trials, 1 STAT. MED. 345, 346 
(1982).  
 3. See, e.g., Donald D. Price, Damien G. Finniss & Fabrizio Benedetti, A 
Comprehensive Review of the Placebo Effect: Recent Advances and Current Thought, 
59 ANN. REV. PSYCHOL. 565 (2008).  
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results. Without blinding and placebo-controls, it is impossible to separate how 
much of the effect demonstrated in the study is due to these subconscious 
changes and how much is due to the medical device. Evidence of device effec-
tiveness is thus not as strong as patients, physicians, and regulators may desire. 
Scientifically rigorous studies of the safety and effectiveness of Class 
III medical devices are necessary, however, given that such devices are “high-
risk devices that are very important to health or sustaining life”4 or “present a 
potential, unreasonable risk of illness or injury.”5 In the best scientifically de-
signed trials, in order to test for an effect of a medical device that is surgically 
implanted, patients are randomized into a condition in which a “sham” proce-
dure is conducted to control for the placebo effect, and the patients and evalua-
tors are blinded as to whether the patient received the “real” or the “sham” de-
vice. There are ethical concerns about such studies because, although they are 
scientifically superior to non-randomized, unblinded, or uncontrolled studies, 
the sham arm of the trial may impose greater than minimal risk on study sub-
jects for no corresponding direct benefit. 
Much of the scholarly discussion on “sham” surgeries occurred in the late 
1990s through the mid-2000s in response to a study in which investigators 
transplanted fetal tissue into the brains of patients with Parkinson’s disease and 
used a sham surgery as a control to assess whether the intervention was effec-
tive.6 The issue of sham-controlled studies is emerging in importance again, 
however, as the FDA has recently been encouraging more Class III medical de-
vices to be tested for safety and effectiveness in randomized, double-blinded, 
placebo-controlled studies,7 the study design preferred for pivotal trials of ex-
 4. Jill Jin, FDA Authorization of Medical Devices, 311 J. AM. MED. ASS’N 435 (2014). See 
also 21 C.F.R. § 860.93 (2014). 
 5. Premarket Approval (PMA), FOOD & DRUG ADMIN. (Aug. 19, 2014), http://www.fda 
.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/ 
PremarketSubmissions/PremarketApprovalPMA/default.htm.  
 6. See, e.g., Thomas B. Freeman, Dorothy E. Vawter, Paul E. Leaverton, James H. 
Godbold, Robert A. Hauser, Christopher G. Goetz & C. Warren Olanow, Use of 
Placebo Surgery in Controlled Trials of a Cellular-Based Therapy for Parkinson’s 
Disease, 341 NEW ENG. J. MED. 988 (1999) (describing the Parkinson’s study); Ruth 
Macklin, The Ethical Problems with Sham Surgery in Clinical Research, 341 NEW 
ENG. J. MED. 992 (1999) (critiquing the ethics of the sham intervention in the 
Parkinson’s study). 
 7. FDA, DESIGN CONSIDERATIONS FOR PIVOTAL CLINICAL INVESTIGATIONS FOR 
MEDICAL DEVICES: GUIDANCE FOR INDUSTRY, CLINICAL INVESTIGATORS, 
INSTITUTIONAL REVIEW BOARDS AND FOOD AND DRUG ADMINISTRATION STAFF 31-32 
(2013), http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationand 
Guidance/GuidanceDocuments/UCM373766.pdf. See also Thomas M. Burton, Do 
the FDA’s Regulations Governing Medical Devices Need to be Overhauled?, WALL ST. 
J. (Mar. 23, 2015), http://www.wsj.com/articles/do-the-fdas-regulations-of-medical 
-devices-need-to-be-overhauled-1427079649; Scott Gottlieb, The FDA Wants You 
for Sham Surgery, WALL ST. J. (Feb. 18, 2014), http://www.wsj.com/articles/ 
SB10001424052702304680904579365414108916816; ANN QUINLAN-SMITH & RITA 
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perimental drugs.8 To date, most Class III devices have been approved on the 
basis of non-randomized, unblinded, or non-placebo-controlled trials, which 
makes the effectiveness of the devices questionable. 
In this paper, I evaluate the ethical implications of the FDA’s move to en-
courage randomized, double-blinded, sham-controlled trials for Class III devic-
es when such studies are possible. In Part I, I describe the placebo effect and 
how researchers control for it. In Part II, I describe the results of studies of 
medical procedures and devices that have used a sham control. In Part III, I de-
scribe the ethical concerns surrounding the use of sham surgeries to study med-
ical devices. In Part IV, I argue for the use of randomized, double-blinded, 
sham-controlled device trials, and propose an ethical framework for these stud-
ies. 
  
I. FDA Requirements for Device Approval and Placebo Controls 
 
The FDA requires that “valid” scientific studies of Class III devices provide 
“reasonable assurance” that such devices are safe and effective prior to their ap-
proval.9 In order to demonstrate effectiveness, devices must be compared to a 
“control.”10 One such control is a placebo control (or “sham” device), which is 
particularly helpful when it is known or suspected that the real device will have 
a placebo effect.11 
A placebo effect occurs when there is an effect from participating in a study 
that is not due to the effectiveness of the intervention being examined.12 Such 
effects have been documented for both objective and subjective endpoints.13 
This effect could be from the research subject’s expectations of improvement14 
KRAUS, N. AM. SCI. ASSOCIATES, CURRENT TRENDS AT THE FDA: IMPLICATIONS FOR 
DATA REQUIREMENTS, https://www.namsa.com/wp-content/uploads/2015/10/ 
NAMSA_-_Current_Trends_at_FDA-Implications_for_Data_Requirements 
_Jan2013.pdf.  
 8. The FDA does exercise some regulatory flexibility, however, which means that 
some drugs are approved without being subjected to such studies. This means the 
clinical evidence of safety and efficacy is not as strong as it could be for some drugs 
approved by the FDA. See JERRY AVORN, POWERFUL MEDICINES 71 (2005). 
 9. 21 C.F.R. § 860.7(c)(1)-(2) (2012). 
 10. 21 C.F.R. § 860.7(f)(1)(iv). See also FDA, supra note 7, at 29-32 (describing types of 
controls). 
 11. See FDA, supra note 7, at 35.  
 12. Id. at 31. 
 13. Id. at 31-32, 35-36. 
 14. Id. at 31. This is known as a therapeutic placebo effect. Alex John London & Joseph 
B. Kadane, Placebos that Harm: Sham Surgery Controls in Clinical Trials, 11 STAT. 
METHODS IN MED. RES. 413, 423 (2002). 
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or changed behavior due to study participation.15 It could also be from the re-
ceipt of better clinical care, spontaneous recovery, or regression toward the 
mean.16 Placebo effects can be substantial, especially for studies involving sur-
geries,17 and long in duration.18 
In order to control for the placebo effect, a “sham” device can be used.19 
This device is designed to be ineffective, and so any effect demonstrated from its 
use is known to be a placebo effect, the size of which can then be compared to 
the effect size from the device being tested. If the effect from the real device is 
larger than the effect from the sham device, this is strong evidence of the de-
vice’s effectiveness.20 Using a sham device as a control, along with a random-
ized, double-blinded study design,21 allows for an isolation of the effect due 
solely to the device being tested. 
Because the placebo effect introduces bias into the study, recent FDA guid-
ance recommends using a placebo control in studies of device effectiveness 
whenever possible in order to control for this effect22—that is, to equalize the 
placebo effect across conditions.23 The FDA recognizes that not all devices 
should be studied in this way, however. The FDA discusses ethical concerns of 
sham device controls in multiple places in the guidance document, particularly 
when these studies involve denying therapy to a group of subjects.24 The FDA 
also considers the possibility and practicality of randomized, double-blinded, 
sham-controlled trials, noting that the scientifically preferred study design will 
not be feasible for some devices.25 
 15. FDA, supra note 7, at 31-32, 35.  
 16. Id. at 32; London & Kadane, supra note 14, at 422-23.  
 17. Remy L. Brim & Franklin G. Miller, The Potential Benefit of the Placebo Effect in 
Sham-Controlled Trials: Implications for Risk-Benefit Assessments and Informed 
Consent, 39 J. MED. ETHICS 703, 704 (2013). 
 18. FDA, supra note 7, at 31.  
 19. Id. at 31. 
 20. Id. 
 21. The FDA also recommends randomization of subjects into different arms of the 
study and the blinding of all parties to the study—patients, investigators, and 
evaluators—whenever possible to reduce bias. If one or more of the parties is not 
blinded, then expectations and behavior change, which introduces bias of 
unknown size into the study regardless of whether subjects were randomized or 
not. FDA, supra note 7, at 31-37.  
 22. Id. at 31-32, 35-36.  
 23. Brian R. Wolf & Joseph A. Buckwalter, Randomized Surgical Trials and “Sham” 
Surgery: Relevance to Modern Orthopaedics and Minimally Invasive Surgery, 26 
IOWA ORTHOPAEDIC J. 107, 107 (2006). 
 24. See, e.g., FDA, supra note 7, at 35.  
 25. Id. at 35-36; see also Richard J. Rohrer, Sham Surgery, 14 AM. MED. ASS’N J. ETHICS 
227, 228 (2012). 
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Published FDA guidance strongly encourages researchers to contact the 
FDA for technical assistance when designing medical device study protocols in 
order to receive FDA feedback prior to finalizing study protocols and submit-
ting them for formal FDA review.26 It is through this consultation between re-
searchers and the FDA that decisions are made about whether a sham-
controlled study will appropriately answer questions about the safety and effec-
tiveness of the particular device. While there are other controls the FDA may 
consider acceptable for device studies,27 all suffer from methodological weak-
nesses such as lack of blinding28 or differing sizes of placebo effects.29 Thus, the 
FDA has been requiring studies to use randomized, double-blinded, sham-
controlled trials more frequently.30 
 
II. Findings from Studies Using Sham Surgeries or Devices 
 
Conducting randomized, double-blinded, placebo-controlled drug trials in 
order to determine a drug’s effectiveness is common. However, it is more diffi-
cult to conduct such studies of medical devices.31 Because of this difficulty, 
many devices have not been subjected to the most scientifically rigorous studies 
 26. See, e.g., FDA, supra note 7, at 11, 17-18, 51.  
 27. Id. at 30-31.  
 28. Id. at 36.  
 29. Id. at 32; Theodore J. La Vaque & Thomas Rossiter, The Ethical Use of Placebo 
Controls in Clinical Research: The Declaration of Helsinki, 26 APPLIED 
PSYCHOPHYSIOLOGY & BIOFEEDBACK 23, 24 (2001). The placebo effect size is larger 
for surgeries than for drugs. Brim & Miller, supra note 17, at 704. However, some 
argue that using the standard treatment as an active control can adequately 
demonstrate the effectiveness of the experimental treatment. See La Vaque 
& Rossiter, supra, at 31; Sophie L. Niemansburg, Johannes J. M. van Delden, 
Wouter J. A. Dhert & Annelien L. Bredenoord, Reconsidering the Ethics of Sham 
Interventions in an Era of Emerging Technologies, 157 SURGERY 801, 804 (2015). 
 30. This is despite any objections from researchers, clinicians, or the public. See, e.g., 
Gottlieb, supra note 7; (questioning the utility and ethics of sham surgery 
involving a cardiovascular device); Niemansburg et al., supra note 29, at 805 
(describing possible objections by researchers and public to sham surgeries); 
Quinlan-Smith & Kraus, supra note 7, at 2 (describing physicians who felt some 
clinical trial designs were unethical); Wolf & Buckwalter, supra note 23, at 109 
(describing potential public aversion to sham surgeries). Such objections to sham 
surgeries may be overstated, however, as empirical research has demonstrated 
support for sham-controlled trials. Samuel A. Frank, Renee Wilson, Robert G. 
Holloway, Carol Zimmerman, Derick R. Peterson, Kark Kieburtz & Scott Y.H. 
Kim, Ethics of Sham Surgery: Perspective of Patients, 23 MOVEMENT DISORDERS 63 
(2008); Niemansburg et al., supra note 29, at 805. 
 31. See Freeman et al., supra note 6, at 988.  
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for effectiveness.32 A device may demonstrate an effect, but it may largely or on-
ly be due to investigator bias or the placebo effect.33 
The few studies that have examined surgical procedures or devices using a 
sham control have found no effect of the surgical procedure or device relative to 
the sham procedure or device.34 For example, recent research has shown that, 
twelve months out, a common surgical intervention to treat meniscal tears as-
sociated with degenerative knee disease is no more effective than a sham sur-
gery.35 In this procedure, the surgeon removes “torn meniscal fragments and 
[trims] the meniscus back to a stable rim.”36 It was impossible to know this 
treatment was ineffective without comparing it to a sham because those under-
going the surgery experienced a placebo effect, which made the surgical inter-
vention appear to be effective.37 Prior to this study, patients had been subjected 
to the risks of surgery for no benefit beyond the placebo effect; patients and 
health insurers had paid for an ineffective intervention;38 and intellectual and 
financial resources may also have been diverted from identifying an effective 
treatment for degenerative knee disease given popular belief that this interven-
tion was effective. 
Even more recently, a Medtronic blood pressure device, the Symplicity Re-
nal Denervation System, was found to have no benefit relative to a sham device, 
according to preliminary study results.39 According to the manufacturer’s web-
site, the device, a catheter and generator that is inserted into the renal arteries, 
“emits a radio frequency (RF) energy across multiple electrodes . . . to disrupt 
the nerves,” which is thought to provide the proper energy to control hyperten-
 32. Id. at 988; Daniel B. Kramer, Shuai Xu & Aaron S. Kesselheim, Regulation of 
Medical Devices in the United States and European Union, 366 NEW ENG. J. MED. 
848, 852 (2012); Burton, supra note 7. 
 33. See Freeman et al., supra note 6, at 991 (describing how some medical 
interventions are not evaluated using the gold standard of randomized, double-
blinded, placebo-controlled studies, and thus the effectiveness of such 
interventions is unproven).  
 34. Rohrer, supra note 25, at 229.  
 35. Raine Sihvonen, Mika Paavola, Antii Malmivaara, Ari Itälä, Antii Joukainen, 
Heikki Nurmi, Juha Kalske & Teppo L.N. Järvinen, Arthroscopic Partial 
Meniscectomy versus Sham Surgery for a Degenerative Meniscal Tear, 369 NEW ENG. 
J. MED. 2515 (2013). 
 36. Id. at 2516.  
 37. Id. 
 38. See also Burton, supra note 7. 
 39. Gottlieb, supra note 7; Joseph Walker, Medtronic Blood Pressure Device Misses Goal 
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sion.40 On the basis of other, non-sham-controlled studies, the Symplicity Renal 
Denervation System was considered a “miracle” in reducing high blood pres-
sure in patients that did not respond to drug treatment.41 The E.U. approved 
the device,42 and it is in use in Europe,43 but the FDA required a sham-
controlled study design to demonstrate safety and effectiveness prior to approv-
al in the U.S.44 While the device manufacturer describes the procedure as “min-
imally invasive,”45 this procedure and device exposed European patients to the 
risks and costs of surgery for nothing more than a placebo effect. 
 
III. Ethical Critiques of Sham Surgery and Device Studies 
 
The medical, bioethical, and philosophical literatures abound with ethical 
critiques of studies that use sham surgeries to evaluate the effectiveness of medi-
cal procedures and devices.46 For many commentators, despite the scientific 
benefits that come from randomized, double-blinded, sham-controlled trials, 
such studies are too unethical to conduct.47 
One common critique is that clinician-investigators conducting sham-
controlled trials knowingly expose patients to the risks of surgery with no pro-
 40. Symplicity RDN System, MEDTRONIC, http://www.medtronicrdn.com/intl/ 
healthcare-professionals/about-rdn/about-the-procedure/index.htm (last visited 
June 25, 2015). 
 41. Joseph Walker, Medtronic Makes Surprise Turn on Blood-Pressure Device, WALL ST. 
J. (Mar. 29, 2014), http://www.wsj.com/articles/SB1000142405270230468810457 
9468500895597252.  
 42. In 2012, the FDA published a report on dangerous and ineffective devices that were 
approved in the European Union on the basis of limited evidence of safety and 
without evidence of benefit to patients. Most of the devices described were unsafe 
rather than ineffective. FDA, UNSAFE AND INEFFECTIVE DEVICES APPROVED IN THE 
EU THAT WERE NOT APPROVED IN THE US (May 2012), http://www.elsevierbi.com/ 
~/media/Supporting%20Documents/The%20Gray%20Sheet/38/20/FDA_EU 
_Devices_Report.pdf. The U.S. arguably has a more robust regulatory system for 
medical device approval than the E.U., which makes it less likely that unsafe 
devices will make it to the market, although some still do. However, because many 
devices approved by the FDA were not tested in the most rigorous type of clinical 
trial, there are still questions about device effectiveness in the U.S. 
 43. Gottlieb, supra note 7; Walker, supra note 39. 
 44. Gottlieb, supra note 7. 
 45. Symplicity RDN System, supra note 40. 
 46. There are methodological critiques of such studies as well. For example, the results 
may not be generalizable because the skill level of surgeons varies. Additionally, 
such studies cannot control for the increasing skill level of the surgeon over the 
course of the study. Freeman et al., supra note 6, at 988. 
 47. See, e.g., Macklin, supra note 6.  
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spect of direct benefit.48 The risks to patients include risks associated with the 
surgery itself, the anesthesia used for the surgery, and any follow-up testing and 
drug treatment.49 This is in addition to the risks of forgoing or delaying other 
possible treatment.50 Furthermore, unlike in randomized, double-blinded, pla-
cebo-controlled drug trials, surgeons51 are forced to actively deceive patients in 
cases in which sham surgery is conducted.52 
Another common critique is that while society as a whole may benefit from 
sham-controlled medical device trials as scientific knowledge advances, this 
benefit accrues at the expense of the research participants who do not benefit 
and are, in fact, harmed, and thus this study design violates the Declaration of 
Helsinki.53 Some commentators argue that scientific advancement should not 
be prioritized over the ethical treatment of human subjects.54 
Finally, some claim that forcing devices to go through sham-controlled tri-
als instead of non-inferiority studies in which the control is an effective treat-
 48. See, e.g., Freeman et al., supra note 6, at 988; Gottlieb, supra note 7; Macklin, supra 
note 6, at 993.  
 49. See, e.g., Freeman et al., supra note 6, at 990; London & Kadane, supra note 14, at 
417; Macklin, supra note 6, at 993; Wolf & Buckwalter, supra note 23, at 108; 
Franklin G. Miller, Sham Surgery: An Ethical Analysis, 10 SCI. ENG’G ETHICS 157, 160 
(2004). 
 50. See, e.g., Freeman et al., supra note 6, at 990; London & Kadane, supra note 14, at 
417; Macklin, supra note 6, at 993. These risks may also be present in drug trials 
that use a placebo, although some scholars view this as less controversial than 
sham controls in device trials because often this is not considered a “harm.” 
London & Kadane, supra note 14, at 425; Miller, supra note 49, at 158; Sheryl Gay 
Stolberg, Ideas & Trends: Sham Surgery Returns as a Research Tool, N.Y. TIMES 
(Apr. 25, 1999), http://www.nytimes.com/1999/04/25/weekinreview/ideas-trends 
-sham-surgery-returns-as-a-research-tool.html. Some, however, believe it is 
unethical to withhold the standard effective treatment in order to study a new 
treatment, regardless of whether it is a drug or device trial. See, e.g., La Vaque & 
Rossiter, supra note 29, at 25, 34; Macklin, supra note 6, at 993. 
 51. These studies can still be double-blinded if the surgeon is not the investigator or 
independent evaluator. 
 52. Macklin, supra note 6, at 995; Franklin G. Miller & Ted J. Kaptchuk, Sham 
Procedures and the Ethics of Clinical Trials, 97 J. ROYAL SOC’Y MED. 576 (2004). 
 53. See La Vaque & Rossiter, supra note 29, at 25; Wolf & Buckwalter, supra note 23, at 
108. The Declaration of Helsinki was first adopted by the World Medical 
Association in 1964, and provides ethical guidelines for conducting medical 
research on human subjects. WORLD MED. ASS’N, DECLARATION OF HELSINKI: 
ETHICAL PRINCIPLES FOR MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS (2013), 
http://www.wma.net/en/30publications/10policies/b3/index.html.  
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ment or device55 delays getting devices to the market, which may be to the det-
riment of patients if the device is proven to work.56 
 
IV. The Need for Randomized, Double-Blinded, Sham-Controlled   
Device Trials 
 
Much of the discussion and debate about the ethics of studies involving 
sham surgeries focuses on the possible harm to subjects participating in the 
sham arm of the study. Counterbalancing these considerations, however, is the 
possible harm to persons using ineffective devices that they believe are effective 
because the FDA has approved them based on non-randomized, unblinded, or 
non-sham-controlled studies. If it is possible, practicable, and not too risky to 
conduct a scientific study to determine whether a device is effective beyond the 
placebo effect, and such a study is not conducted, it is unethical to market these 
possibly ineffective high-risk Class III devices.57 The FDA should encourage de-
vice manufacturers to provide only truly effective Class III devices. 
Randomized, double-blinded, sham-controlled trials should thus be con-
ducted whenever possible, practicable, and in accord with the Common Rule 
guidelines on human subjects research in order to secure FDA approval for 
Class III medical devices.58 Such study design is the scientifically superior means 
by which to demonstrate the effectiveness of a device, particularly when end-
points are patient-reported or subjective,59 and it reduces investigator bias.60 
Furthermore, sham surgeries can now be less invasive and risky than in the 
 55. 21 C.F.R. § 860.7(f)(1)(iv)(c) (2012); Gottlieb, supra note 7. 
 56. Gottlieb, supra note 7; Walker, supra note 39. 
 57. As Miller asked: “Can it be ethical not to use sham surgery to evaluate rigorously a 
surgical procedure before it is introduced into practice under the following 
conditions: when methodological reasons indicate that a sham surgery control is 
needed to demonstrate efficacy and the risks of the sham procedure are not 
excessive and justified by the value of the knowledge to be gained from the study?” 
Miller, supra note 49, at 165. 
 58. Admittedly, such studies may not always be possible. Kramer, Xu & Kesselheim, 
supra note 32, at 852-53; Rohrer, supra note 25, at 228. Post-market surveillance 
studies can help determine safety and effectiveness of high-risk, implantable 
devices. Kramer, Xu & Kesselheim, supra note 32, at 853. However, the FDA does 
not have enough resources to adequately surveil all devices on the market. INST. OF 
MED., MEDICAL DEVICES AND THE PUBLIC’S HEALTH: THE FDA 510(K) CLEARANCE 
PROCESS AT 35 YEARS 103, 128 (2011) (“The Government Accountability Office 
(formerly the General Accounting Office) reported in 1989 and again in 2009 that 
the FDA was unable to manage its postmarket-surveillance responsibilities because 
of resource constraints . . . .”). 
 59. Miller, supra note 49, at 157. 
 60. Wolf & Buckwalter, supra note 23, at 110. 
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past,61 making the risk-benefit ratio of the research easier to evaluate and less 
controversial.62 
This Part will first respond to the ethical critiques summarized in Part III, 
and then outline procedural safeguards that can facilitate ethical randomized, 
double-blinded, sham-controlled Class III medical device trials. 
 
A. Response to Ethical Critiques of Sham Device Study Designs 
 
In response to arguments about potentially unjustified risks to participants 
in the sham arm of medical device studies, some critics contend that sham pro-
cedures may be justified in cases where there is clinical equipoise.63 Equipoise 
exists when “one’s judgment is ‘equally balanced’ with regard to the issue of 
help or harm that may ensue from assigning a patient to either the placebo or 
treatment group.”64 This equipoise may come after a study of a device shows 
that it is more effective than the standard treatment, but leaves clinicians uncer-
tain as to whether the effect is due to the placebo effect.65 
Furthermore, some of the concerns regarding sham surgeries are mini-
mized when the surgeries are not extreme. Many commentators reacted strong-
ly to the Parkinson’s disease fetal-tissue implantation clinical trials because of 
the type of sham surgery performed.66 In the study, surgeons drilled holes into 
the skulls of patients in the control group not having fetal-tissue implanted into 
their brains in order to make patients think they were in the treatment group, 
thus controlling for the placebo effect.67 Importantly, this study design demon-
strated that this high-risk treatment was ineffective.68 Risks differ depending 
upon the procedure, however, and many sham procedures may be quite benign, 
such as a small skin incision and the use of local rather than general anesthe-
sia.69 
 61. See, e.g., Rohrer, supra note 25; Stolberg, supra note 50. 
 62. Some argue that because the risk-benefit ratio of sham surgeries is too uncertain, 
such surgeries should not be performed. See, e.g., Macklin, supra note 6, at 993-94. 
Others suggest that minimally invasive sham procedures may be ethically 
permissible. See, e.g., Gottlieb, supra note 7.  
 63. La Vaque & Rossiter, supra note 29, at 29-30; London & Kadane, supra note 14, 419-
422. 
 64. La Vaque & Rossiter, supra note 29, at 29.  
 65. Id. There are debates about how to determine whether equipoise exists, however. 
Id. at 29-30; London & Kadane, supra note 14, at 420-21.  
 66. See, e.g., Macklin, supra note 6, at 995. 
 67. Freeman et al., supra note 6, at 989-90. 
 68. See Joshua David Rosenberg, Informed Consent and Sham Surgery as a Placebo in 
Fetal Cell Transplant Therapy Research for Parkinson’s Disease, 20 EINSTEIN J. BIO. 
MED. 14, 14 (2003) (describing the results of the Parkinson’s studies). 
 69. See Miller, supra note 49, at 163-64; Wolf & Buckwalter, supra note 23, at 109.  
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Moreover, many of the aforementioned ethical concerns about risks to par-
ticipants can be eliminated if a distinction is made between clinical ethics and 
research ethics, or clinical care and clinical research.70 Clinicians and research 
scientists have different obligations toward patients, and in the case of medical 
device trials, the appropriate ethical standard for clinician-investigators is 
whether they are acting as ethical researchers. As Miller and Kaptchuk note: 
“Professional integrity for investigators conducting sham-procedure trials is 
preserved only by recognition that they are operating primarily as scientists, not 
as clinicians.”71 What may be considered unethical for a clinician who must act 
in their patient’s best interest may not be considered unethical for a researcher 
as long as the risks of study participation are not excessive and have been min-
imized, the study has scientific value that justifies the risks, and informed con-
sent has been obtained. Many people, after all, participate in studies with great-
er than minimal risk where there is only societal rather than direct individual 
benefit.72 
When considering the objection that sham-controlled studies benefit sci-
ence and society at the expense of participants, one can look for guidance in 
The Belmont Report.73 The Belmont Report is one of the primary influences on 
United States human subjects research regulations; the Federal Policy for the 
Protection of Human Subjects is known as the Common Rule, which has been 
codified by many federal agencies.74 The Belmont Report discusses the balanc-
ing of the interests of the individual and society,75 and this is reflected in the 
Common Rule.76 Empirical evidence also suggests that the majority of patients 
and the vast majority of clinician-investigators think it is ethically permissible 
for Institutional Review Boards (IRBs) to approve sham surgery studies, even if 
patients may prefer to participate in an unblinded trial.77 
 70. Miller, supra note 49, at 158-59; Miller & Kaptchuk, supra note 52, at 577. 
 71. Id. 
 72. See Miller, supra note 49, at 164. 
 73. The Belmont Report was published in 1979 and describes ethical principles that 
should govern research on human subjects. NAT’L COMM’N FOR THE PROT. OF 
HUMAN SUBJECTS OF RESEARCH, THE BELMONT REPORT (Apr. 18, 1979), http://www 
.hhs.gov/ohrp/humansubjects/guidance/belmont.html. 
 74. Federal Policy for the Protection of Human Subjects (‘Common Rule’), OFFICE FOR 
HUMAN RESEARCH PROTS., U.S. DEP’T. OF HEALTH & HUMAN SERVS., http://www 
.hhs.gov/ohrp/humansubjects/commonrule/index.html [hereinafter Common 
Rule] (last visited Sept. 4, 2015). 
 75. Id. “Assessment of Risks and Benefits.” See also Wolf & Buckwalter, supra note 23, 
at 108.  
 76. Common Rule, supra note 74. The U.S. Department of Health and Human Services 
regulations can be found at 45 C.F.R. § 46 (2009).  
 77. Frank et al., supra note 30, at 68. Only half of Parkinson’s disease clinical 
researchers surveyed thought unblinded studies should be approved, and 94% 
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Finally, some contend that sham-controlled studies delay the entry of de-
vices into the market, and that this delay harms patients.78 However, devices 
that are approved quickly without being rigorously studied for effectiveness 
may ultimately be found to be ineffective79 or even unsafe,80 resulting in subse-
quent market withdrawal that may also be to the detriment of patients. 
 
B. Procedural Safeguards to Facilitate Ethical Randomized, Double-Blinded, 
Sham-Controlled Device Trials 
 
Given the ethical concerns described in Part III, there should be standard 
safeguards built into the study design, approval, and informed consent process 
for proposed sham-controlled studies. Each proposed sham-controlled study 
must still, however, be individually analyzed for its risks and benefits to ensure 
that the study design meets the Common Rule guidelines.81 
The first set of safeguards relates to study design. Because of the increased 
risk to participants from sham surgery relative to using other possible controls 
or relative to the placebos used in drug trials, only rigorous study designs 
should be approved. This means that there should be a study design appropri-
ately powered to answer the research questions,82 blinding of all parties in-
volved in the research,83 and “accurate and complete data collection.”84 Addi-
tionally, only investigators, surgeons, and evaluators with the necessary skill 
level should be involved in carrying out the study to ensure that the above re-
quirements are met. Given the additional risks to subjects, it would be unethical 
approved of sham surgeries to study treatments for the disease. This study suggests 
a disconnect between investigators and potential research subjects in evaluating 
proposed research. Id. at 67. There may also be a disconnect between researchers 
and practitioners, the latter of whom may want to know how two treatments 
compare with one another, in which case blinding may not be possible, rather 
than how a treatment compares with nothing. La Vaque & Rossiter, supra note 29, 
at 31. 
 78. See, e.g., Gottlieb, supra note 7. 
 79. See, e.g., Kramer, Xu & Kesselheim, supra note 32, at 852; Walker, supra note 39; 
Gottlieb, supra note 7. 
 80. Burton, supra note 7. 
 81. See Miller, supra note 49, at 165. 
 82. Freeman et al., supra note 6, at 989. 
 83. Id. at 990; FDA, supra note 7, at 31-32, 35-36; Wolf & Buckwalter, supra note 23, at 
110. Even when evaluators are blinded, patients often unblind them. Miller, supra 
note 49, at 162.  
 84. Freeman et al., supra note 6, at 989. 
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to carry out a study of this nature without ensuring that the question of whether 
the device is safe and effective can be confidently answered.85 
The second set of safeguards relates to study approval. All studies, regard-
less of design, must abide by the Common Rule regulations, which direct Insti-
tutional Review Boards to consider the risk-benefit profile of the study86 and 
require that risks to subjects be minimized as much as possible.87 This means 
that some sham device studies, although scientifically superior to other study 
designs, may not be approved if the risks to subjects are too extreme.88 Howev-
er, this may also mean that some studies that are approved expose subjects to 
greater than minimal risk.89 Miller has asserted that the ceiling of risk for sham 
procedure controls “should be no greater than what would be permitted in 
nontherapeutic studies aimed at understanding pathophysiology.”90 Brim and 
Miller have also argued that the benefit of the therapeutic placebo effect91 
should be factored into the risk-benefit analysis of these studies, especially given 
that the magnitude of the effect is larger for surgical interventions compared to 
drug trials; doing so will make it more likely that such studies will be ap-
proved.92 
The FDA should also consider whether the device targets an important 
medical need in order to justify the risks associated with the sham device trial.93 
 85. The studies should have both scientific and clinical value. See Freeman et al., supra 
note 6, at 988-89; Miller, supra note 49, at 163-64.  
 86. 45 C.F.R. § 46.111 (2009). Empirical evidence suggests that there is a disconnect 
between how researchers and subjects view research design. Frank et al., supra 
note 30, at 67. IRBs and government regulatory agencies should thus consult with 
patient advocates or patients for their viewpoint when reviewing studies that 
propose to use a sham device. 
 87. 45 C.F.R. § 46.111(a)(1). See also Freeman et al., supra note 6, at 988; Miller, supra 
note 49, at 163. 
 88. See Miller, supra note 49, at 163-64; Brim & Miller, supra note 17, at 704. 
 89. See Miller, supra note 49, at 164. This may be permissible if “[r]isks to subjects are 
reasonable in relation to anticipated benefits, if any, to subjects, and [reasonable] 
to the importance of the knowledge that may reasonably be expected to result.” 
45 C.F.R. § 46.111(a)(2). 
 90. Miller, supra note 49, at 164. That is, the ceiling is the risks permitted when healthy 
subjects volunteer for Phase I clinical trials.  
 91. Brim & Miller, supra note 17, at 703. 
 92. They argue this because the federal regulations say that all benefits need to be 
taken into consideration in the risk-benefit analysis, and all benefits need to be 
disclosed during the informed consent process. Brim & Miller, supra note 17, at 
705. They assert that disclosing the placebo effect to prospective participants may 
actually increase enrollment in sham-controlled trials if participants know that 
they will receive some benefit from participating. Id.  
 93. Once more, the studies should have both scientific and clinical value. See Freeman 
et al., supra note 6, at 988-89; Miller, supra note 49, at 163-64. 
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It may be that there are already effective devices on the market, that alternative 
effective treatments are available, or that the condition is not serious enough to 
warrant a device targeted at it.94 
The third set of safeguards involves informed consent, which is required as 
part of all research participation.95 In the case of studies in which a sham device 
is used as a control, however, extra steps should be taken in the informed con-
sent process.96 One such step may be requiring prospective research partici-
pants to write, rather than just sign, a statement certifying that they understand 
they may be assigned to a condition in which they receive a sham device 
through sham surgery,97 that they understand the risks of surgery,98 and that the 
only such benefit of the study may be a placebo effect.99 Another step may be to 
have a neutral third party, rather than the clinical investigator, go through the 
informed consent process and explain the difference between research and 
medical treatment in an effort to reduce any therapeutic misconception a pro-
spective subject may have.100 These informed consent safeguards mitigate con-
cerns about clinician-researcher deception described above and promote pa-
tient autonomy. Concerns about the possible inequitable accrual of research 
benefits may also be lessened, given that prospective participants would know-
ingly and willingly decide to enter a study in which the benefits of the research 
may largely accrue to society rather than study participants, an option that 
some research suggests many patients would willingly choose.101 
As a final ethical consideration, participants in the sham arm of the trial 
should be provided the device for free if it is found to be effective at the conclu-
 94. “[T]he FDA may consider the severity of the disease and available alternatives 
when evaluating high-risk devices” and may decline to approve such devices if 
there are safe and efficacious alternatives and if the device targets “quality of life 
rather than survival.” Kramer, Xu & Kesselheim, supra note 32, at 849-50. “[T]here 
must be a clinical need for the new device in the healthcare market.” Jin, supra 
note 4, at 435. 
 95. 45 C.F.R. §§ 46.111(a)(4), 46.116. 
 96. Freeman et al., supra note 6, at 989; Rosenberg, supra note 68, at 15-16 (addressing 
sham surgeries). 
 97. Miller, supra note 49, at 164-65. 
 98. See Rosenberg, supra note 68, at 17. 
 99. Brim & Miller, supra note 17, at 705. The language in the informed consent 
document may even be stronger: that participants will experience a placebo effect. 
This is because research has demonstrated large placebo effects in sham surgery 
studies. Id.; but see London & Kadane, supra note 14, at 424 (arguing that placebo 
effects should not be considered benefits and that they may actually be harmful). 
 100. See, e.g., Macklin, supra note 6, at 994 (describing the potential for therapeutic 
misconception); Rosenberg, supra note 68, at 17 (describing how to attack the 
therapeutic misconception); Wolf & Buckwalter, supra note 23, at 109 (describing 
the potential for therapeutic misconception). 
 101. Frank et al., supra note 30, at 67. 
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sion of the study.102 Another variation on this is to implant devices in all sub-
jects, but only activate the devices in some (randomly and blindly).103 This way, 
if the device is effective, a second procedure does not need to be conducted; 
even if the device is not effective, subjects will still benefit from the therapeutic 





As the FDA is beginning to promote the use of randomized, double-
blinded, sham-controlled Class III medical device trials,105 in order to control 
for unconscious investigator bias from lack of blinding or the well-documented 
behavioral and physiological responses patients experience as a placebo effect,106 
it is necessary to determine whether this is an ethical policy. I have argued that 
with proper safeguards, along with an appropriate risk-benefit profile and in-
formed consent, such studies can be ethical. Given the scientific superiority of 
such studies, the FDA should insist on this study design when it is possible, 
practicable, and ethical. This policy will ultimately benefit patients: although 
they may have delayed access to devices given the time it takes to conduct such 
studies, once a device is available, they will be assured access to a demonstra-
tively effective device.107 
 
 
 102. See Freeman et al., supra note 6, at 990; Sihvonen et al., supra note 35, at 2516; 
Gottlieb, supra note 7. 
 103. See, e.g., Rohrer, supra note 25 (summarizing this design for a device meant to 
combat obesity); Andres M. Lozano & Helen S. Mayberg, Treating Depression at 
the Source, SCI. AM., Feb. 2015, at 68-73 (describing a study of deep brain 
stimulation used to treat depression symptoms where all study subjects received 
implants, but the FDA required that a group of subjects not have their electrodes 
on for six months; there was no difference in relief of depression between the two 
groups). See also Gottlieb, supra note 7 (arguing that a sham component to a real 
surgery is ethically permissible).  
 104. See Brim & Miller, supra note 17, at 703. 
 105. FDA, supra note 7, at 31-32; Burton, supra note 7; Gottlieb, supra note 7. 
 106. Price, Finniss & Benedetti, supra note 3. 
 107. FDA, supra note 42, at 14-15; Kramer, Xu & Kesselheim, supra note 32, at 852; 
Walker, supra note 39.  
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